Dermatology Drugs market is projected to grow at a CAGR of 6.2% by 2032: Visiongain Reports Ltd
29 déc. 2022 09h00 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Dermatology Drugs 2022-2032. It includes profiles of Dermatology Drugs and Forecasts Market Segment by Disease (Psoriasis, Dermatitis, Acne, Skin...
Dermatology Drugs market is projected to grow at a CAGR of 6.2% by 2032: Visiongain Reports Ltd
21 nov. 2022 11h32 HE
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Dermatology Drugs 2022-2032. It includes profiles of Dermatology Drugs and Forecasts Market Segment by Disease (Psoriasis, Dermatitis, Acne, Skin...
Dermatological Drugs Market is worth US$44.68 Billion by 2031: Visiongain Research Inc
28 mars 2022 10h00 HE
|
Visiongain Ltd
Visiongain has launched a new report Dermatological Drugs Market Report 2021-2031: Forecast By Disease (Psoriasis, Dermatitis, Acne, Skin Infections, Other Diseases) By Skin Infections Drugs...
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
09 nov. 2021 05h45 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera announces preliminary revenue for Q1 2021
08 avr. 2021 10h30 HE
|
Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
26 févr. 2021 09h20 HE
|
Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
14 oct. 2020 04h30 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...
Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021
20 août 2020 13h00 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified...
Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
18 août 2020 05h00 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150...
Supervisory Board of Biofrontera AG renews Management Board appointment
23 juil. 2020 08h30 HE
|
Biofrontera AG
Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today...